MedTrace Logo

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT06773936 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-05-06

No results posted yet for this study

Summary

This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"

Conditions

  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
  • CD19+ Acute Leukemia

Interventions

DRUG

Induction Phase

Asciminib, Dasatinib, Prednisone, and Methotrexate

DRUG

Re-Induction Phase

Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone

DRUG

Post-Remission

Blinatumomab, Dasatinib, Methotrexate and Dexamethasone

DRUG

Maintenance

Asciminib, Dasatinib, Prednisone, and Methotrexate

Sponsors & Collaborators

Principal Investigators

  • Anjali S Advani · SWOG Network Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2029-05-31
Completion
2033-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06773936 on ClinicalTrials.gov